Article

Forbes on 2024-04-26 15:00

A 3x Expected Rise In Mounjaro Sales Is Likely To Drive Eli Lilly’s Q1

The pharmaceutical giant is expected to garner $8.9 billion in sales and $2.46 in adjusted earnings per share, per the consensus estimates.

Related news

Eli Lilly’s Profit Dented by Higher Costs wsj.com
MEli Lilly sues clinics allegedly promoting knockoff variations of Mounjaro mvtelegraph.com
South Carolina , Minnesota , Georgia , Arizona , Texas
Eli Lilly’s New Compliance Chief on His Priorities6 min read wsj.com
Canada
Eli Lilly’s EFFIENT combination use patent found obvious jdsupra.com
California , United States , Switzerland
Eli Lilly’s sees strength in 2017, shares take off seattletimes.com
FHigh stakes: Eli Lilly’s hunt for an Alzheimer’s drug ft.com
South East Asia , China
Eli Lilly’s Antibody Trial Is Paused Over Potential Safety Concern The New York Times
Veterans Affairs
MEli Lilly’s therapy with solanezumab didn’t decelerate the illness mvtelegraph.com
Brigham City
BEli Lilly’s Earnings Raise Hopes for Pharmaceutical Stocks barrons.com
FEli Lilly & Co: US regulator delays decision on Eli Lilly’s Alzheimer’s drug ft.com
MEli Lilly (LLY) Q1 Income 2023 mvtelegraph.com
Poland , Krakow
Eli Lilly Pushes For Fast-Track Approval Of Mounjaro As Weight-Loss Drug Forbes
North Dakota
How Eli Lilly’s Investors Cashed In 90% Capital Gains While Sales Barely Moved?Forbes
What Is Donanemab? Eli Lilly’s Alzheimer’s Drug Gets Delayed Decision From FDA Forbes
Indianapolis
IHere’s what will happen if you stopped taking Eli Lilly’s weight-loss drug invezz.com
ICramer reacts to Eli Lilly’s telehealth service for weight-loss drug invezz.com
FDA approves Eli Lilly's diabetes drug Mounjaro for obesity under new name, Zepbound CNN
United States
IFDA fast tracks Eli Lilly’s obesity drug: ‘this is the Holy Grail’invezz.com
North America
Federal Court finds Eli Lilly’s tadalafil dosage form and process patents invalid jdsupra.com
Canada